$MEIP
MEI Pharma, Inc.

2018 Q3 Form 10-Q Financial Statement

#000119312518322588 Filed on November 08, 2018

View on sec.gov

Income Statement

Concept 2018 Q3 2017 Q3
Revenue $488.0K $283.0K
YoY Change 72.44% -74.18%
Cost Of Revenue $989.0K $618.0K
YoY Change 60.03% -43.51%
Gross Profit -$501.0K -$335.0K
YoY Change 49.55% -16850.0%
Gross Profit Margin -102.66% -118.37%
Selling, General & Admin $3.400M $2.490M
YoY Change 36.55% -7.09%
% of Gross Profit
Research & Development $6.131M $6.064M
YoY Change 1.1% 268.41%
% of Gross Profit
Depreciation & Amortization $13.00K $14.00K
YoY Change -7.14% 0.0%
% of Gross Profit
Operating Expenses $6.131M $6.064M
YoY Change 1.1% 268.41%
Operating Profit -$10.03M -$8.887M
YoY Change 12.9% 105.53%
Interest Expense -$4.510M $100.0K
YoY Change -4610.0% 66.67%
% of Operating Profit
Other Income/Expense, Net -$4.960M
YoY Change
Pretax Income -$14.54M -$8.790M
YoY Change 65.42% 105.85%
Income Tax $1.000K $1.000K
% Of Pretax Income
Net Earnings -$14.54M -$8.788M
YoY Change 65.48% 105.81%
Net Earnings / Revenue -2979.92% -3105.3%
Basic Earnings Per Share -$0.21 -$0.24
Diluted Earnings Per Share -$0.21 -$0.24
COMMON SHARES
Basic Shares Outstanding 70.89M shares 37.25M shares
Diluted Shares Outstanding 70.89M shares 37.25M shares

Balance Sheet

Concept 2018 Q3 2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $90.80M $47.00M
YoY Change 93.19% -20.2%
Cash & Equivalents $6.118M $6.958M
Short-Term Investments $84.60M $40.10M
Other Short-Term Assets $3.700M $600.0K
YoY Change 516.67% -64.71%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $94.44M $47.66M
YoY Change 98.13% -21.4%
LONG-TERM ASSETS
Property, Plant & Equipment $28.00K $45.00K
YoY Change -37.78% -2.17%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $315.0K $367.0K
YoY Change -14.17% -8.93%
TOTAL ASSETS
Total Short-Term Assets $94.44M $47.66M
Total Long-Term Assets $315.0K $367.0K
Total Assets $94.75M $48.03M
YoY Change 97.27% -21.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.555M $751.0K
YoY Change 107.06% 0.27%
Accrued Expenses $2.489M $2.767M
YoY Change -10.05% 13.96%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.784M $4.465M
YoY Change 7.14% -74.07%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $50.20M
YoY Change
Total Long-Term Liabilities $50.20M $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.784M $4.465M
Total Long-Term Liabilities $50.20M $0.00
Total Liabilities $54.99M $4.500M
YoY Change 1122.02% -75.95%
SHAREHOLDERS EQUITY
Retained Earnings -$228.9M -$183.1M
YoY Change 25.02% 1.02%
Common Stock $268.7M $226.7M
YoY Change 18.53% 1.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $39.76M $43.57M
YoY Change
Total Liabilities & Shareholders Equity $94.75M $48.03M
YoY Change 97.27% -21.32%

Cashflow Statement

Concept 2018 Q3 2017 Q3
OPERATING ACTIVITIES
Net Income -$14.54M -$8.788M
YoY Change 65.48% 105.81%
Depreciation, Depletion And Amortization $13.00K $14.00K
YoY Change -7.14% 0.0%
Cash From Operating Activities -$12.82M -$6.562M
YoY Change 95.31% -174.82%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $4.790M $5.040M
YoY Change -4.96% -150.25%
Cash From Investing Activities $4.788M $5.042M
YoY Change -5.04% -150.27%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 837.0K 20.00K
YoY Change 4085.0% -99.52%
NET CHANGE
Cash From Operating Activities -12.82M -6.562M
Cash From Investing Activities 4.788M 5.042M
Cash From Financing Activities 837.0K 20.00K
Net Change In Cash -7.191M -1.500M
YoY Change 379.4% -150.85%
FREE CASH FLOW
Cash From Operating Activities -$12.82M -$6.562M
Capital Expenditures $0.00
Free Cash Flow -$6.562M
YoY Change -174.84%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q2 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
36600000
CY2018Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
71125444 shares
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6958000
CY2018Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1555000
CY2018Q3 us-gaap Assets
Assets
94750000
CY2018Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2489000
CY2018Q3 us-gaap Assets Current
AssetsCurrent
94435000
CY2018Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
268700000
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6118000
CY2018Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
16061602 shares
CY2018Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
113000000 shares
CY2018Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
71115000 shares
CY2018Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
90764000
CY2018Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00000002
CY2018Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
71115000 shares
CY2018Q3 us-gaap Common Stock Value
CommonStockValue
0
CY2018Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
740000
CY2018Q3 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
244000
CY2018Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
740000
CY2018Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
8700000
CY2018Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
287000
CY2018Q3 us-gaap Liabilities
Liabilities
54991000
CY2018Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
94750000
CY2018Q3 us-gaap Liabilities Current
LiabilitiesCurrent
4784000
CY2018Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2018Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2018Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3671000
CY2018Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
3700000
CY2018Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
28000
CY2018Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-228941000
CY2018Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2018Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
6456494
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
10673865
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3344139 shares
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.02
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8043675 shares
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.25
CY2018Q3 us-gaap Short Term Investments
ShortTermInvestments
84646000
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
39759000
CY2018Q3 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
50207000
CY2018Q3 meip Shelf Registration Statement Value
ShelfRegistrationStatementValue
150000000
CY2018Q3 meip Milestone Payments Maximum Amount
MilestonePaymentsMaximumAmount
75200000
CY2018Q3 meip Fair Value Assumptions Exercise Price Warrants Issued
FairValueAssumptionsExercisePriceWarrantsIssued
3.13
CY2018Q3 meip Accounts Receivable Net Beginning Balance
AccountsReceivableNetBeginningBalance
82000
CY2018Q3 meip Accounts Receivable Net Ending Balance
AccountsReceivableNetEndingBalance
213000
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8458000
CY2018Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
3643000
CY2018Q2 us-gaap Assets
Assets
104657000
CY2018Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3454000
CY2018Q2 us-gaap Assets Current
AssetsCurrent
104329000
CY2018Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
264858000
CY2018Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13309000
CY2018Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
113000000 shares
CY2018Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
70406000 shares
CY2018Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
102743000
CY2018Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00000002
CY2018Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
70406000 shares
CY2018Q2 us-gaap Common Stock Value
CommonStockValue
0
CY2018Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
788000
CY2018Q2 us-gaap Contract With Customer Asset Net Current
ContractWithCustomerAssetNetCurrent
312000
CY2018Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
788000
CY2018Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
296000
CY2018Q2 us-gaap Liabilities
Liabilities
54198000
CY2018Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
104657000
CY2018Q2 us-gaap Liabilities Current
LiabilitiesCurrent
7885000
CY2018Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2018Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2018Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1586000
CY2018Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
32000
CY2018Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-214399000
CY2018Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6281615 shares
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.08
CY2018Q2 us-gaap Short Term Investments
ShortTermInvestments
89434000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
50459000
CY2018Q2 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
46313000
CY2018Q2 meip Fair Value Assumptions Exercise Price Warrants Issued
FairValueAssumptionsExercisePriceWarrantsIssued
2.81
CY2018Q2 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
70200000
CY2018Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
21000
CY2018Q3 meip Lease Expiration Month And Year
LeaseExpirationMonthAndYear
2020-05
CY2018Q3 meip Lease Arrangement Rent Area
LeaseArrangementRentArea
7000 sqft
CY2017Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9179000 shares
CY2017Q3 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-1500000
CY2017Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
618000
CY2017Q3 us-gaap Costs And Expenses
CostsAndExpenses
9170000
CY2017Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
14000
CY2017Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
CY2017Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2017Q3 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-49000
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2488000
CY2017Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
CY2017Q3 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
166000
CY2017Q3 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1117000
CY2017Q3 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-18000
CY2017Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
CY2017Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
5042000
CY2017Q3 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
100000
CY2017Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20000
CY2017Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6562000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-8788000
CY2017Q3 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
10041000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8887000
CY2017Q3 us-gaap Profit Loss
ProfitLoss
-8788000
CY2017Q3 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
20000
CY2017Q3 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
4999000
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.021 pure
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.21
CY2017Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
283000
CY2017Q3 us-gaap Revenues
Revenues
283000
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6064000
CY2017Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.976 pure
CY2017Q3 us-gaap Share Based Compensation
ShareBasedCompensation
996000
CY2017Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M24D
CY2017Q3 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
36845000 shares
CY2017Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37245000 shares
CY2017Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37245000 shares
CY2017Q3 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
400000 shares
CY2017Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0 shares
CY2018Q3 dei Amendment Flag
AmendmentFlag
false
CY2018Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
24090000 shares
CY2018Q3 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-7191000
CY2018Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
989000
CY2018Q3 us-gaap Costs And Expenses
CostsAndExpenses
10521000
CY2018Q3 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
CY2018Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
13000
CY2018Q3 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2018Q3 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2018Q3 dei Document Type
DocumentType
10-Q
CY2018Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y10M24D
CY2018Q3 dei Entity Registrant Name
EntityRegistrantName
MEI Pharma, Inc.
CY2018Q3 dei Entity Small Business
EntitySmallBusiness
false
CY2018Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
CY2018Q3 dei Entity Central Index Key
EntityCentralIndexKey
0001262104
CY2018Q3 dei Document Period End Date
DocumentPeriodEndDate
2018-09-30
CY2018Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
CY2018Q3 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2018Q3 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2018Q3 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-48000
CY2018Q3 us-gaap Fair Value Liabilities Measured On Recurring Basis Change In Unrealized Gain Loss
FairValueLiabilitiesMeasuredOnRecurringBasisChangeInUnrealizedGainLoss
-4962000
CY2018Q3 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
48000
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3401000
CY2018Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1000
CY2018Q3 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-2088000
CY2018Q3 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2085000
CY2018Q3 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
131000
CY2018Q3 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-965000
CY2018Q3 us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
68000
CY2018Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
CY2018Q3 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
4788000
CY2018Q3 us-gaap Investment Income Interest And Dividend
InvestmentIncomeInterestAndDividend
454000
CY2018Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
46000
CY2018Q3 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
837000
CY2018Q3 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
324000
CY2018Q3 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12816000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-14542000
CY2018Q3 us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
9725000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-10033000
CY2018Q3 us-gaap Profit Loss
ProfitLoss
-14542000
CY2018Q3 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
43000
CY2018Q3 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
4937000
CY2018Q3 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1118000
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.028 pure
CY2018Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y2M12D
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0 shares
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.11
CY2018Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
488000
CY2018Q3 us-gaap Revenues
Revenues
488000
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6131000
CY2018Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
CY2018Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.27
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.860 pure
CY2018Q3 us-gaap Share Based Compensation
ShareBasedCompensation
1937000
CY2018Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
233854 shares
CY2018Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y
CY2018Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.84
CY2018Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
7.43
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2019250 shares
CY2018Q3 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
70885000 shares
CY2018Q3 dei Trading Symbol
TradingSymbol
MEIP
CY2018Q3 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. We use estimates that affect the reported amounts (including assets, liabilities, revenues and expenses) and related disclosures. Actual results could materially differ from those estimates.</p> </div>
CY2018Q3 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
0 shares
CY2018Q3 meip Exercise Of Warrants For Common Stock
ExerciseOfWarrantsForCommonStock
440043
CY2018Q3 meip Number Of Clinical Stage Candidates
NumberOfClinicalStageCandidates
4 ClinicalTrials
CY2018Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
23336 shares
CY2018Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
70885000 shares
CY2018Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
70885000 shares
CY2018Q3 meip Number Of Candidate In An Ongoing Global Registration Trial
NumberOfCandidateInAnOngoingGlobalRegistrationTrial
1 ClinicalTrials
CY2018Q3 meip Agreement Termination Notice Period
AgreementTerminationNoticePeriod
P90D
CY2018Q3 meip Lease Expiration Month And Year
LeaseExpirationMonthAndYear
2020-05
CY2018Q3 meip Percentage Of Purchases From Major Suppliers
PercentageOfPurchasesFromMajorSuppliers
1.00 pure
CY2018Q3 meip Revenue Remaining Performance Obligation Percentage Of Revenue Expected To Be Recognized Thereafter
RevenueRemainingPerformanceObligationPercentageOfRevenueExpectedToBeRecognizedThereafter
0.42 pure
CY2018Q3 meip Revenue Remaining Performance Obligation Percentage Of Revenue Expected To Be Recognized
RevenueRemainingPerformanceObligationPercentageOfRevenueExpectedToBeRecognized
0.28 pure
CY2018Q3 meip Lease Arrangement Rent Area
LeaseArrangementRentArea
13700 sqft

Files In Submission

Name View Source Status
0001193125-18-322588-index-headers.html Edgar Link pending
0001193125-18-322588-index.html Edgar Link pending
0001193125-18-322588.txt Edgar Link pending
0001193125-18-322588-xbrl.zip Edgar Link pending
d632002d10q.htm Edgar Link pending
d632002dex311.htm Edgar Link pending
d632002dex312.htm Edgar Link pending
d632002dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g632002g95i66.jpg Edgar Link pending
meip-20180930.xml Edgar Link completed
meip-20180930.xsd Edgar Link pending
meip-20180930_cal.xml Edgar Link unprocessable
meip-20180930_def.xml Edgar Link unprocessable
meip-20180930_lab.xml Edgar Link unprocessable
meip-20180930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending